420 with CNW — DEA Opens Rescheduling Hearing by Expressing Support for Reclassification

Federal officials used the opening day of a closely watched administrative hearing on June 29 to reaffirm their support for a proposal that would move marijuana to Schedule 3 under federal law.

Speaking at the DEA’s headquarters in Arlington, Virginia, James J. Schwartz, an attorney with the agency’s Office of Chief Counsel, said the federal government continues to back the proposed change. He told the administrative law judge overseeing the proceedings that the government would present expert testimony to support the recommendation to reclassify marijuana under the Controlled Substances Act.

Schwartz said the government’s role in the hearing is to defend the proposal approved by a previous attorney general. To support its case, federal officials are relying on testimony from a scientific expert and a medical practitioner. The agency’s first witness was FDA scientist Dominic Chiapperino, Ph.D., whose testimony kicked off the hearing.

According to Schwartz, the government’s primary objective is to establish that cannabis has a currently accepted medical use (CAMU) in the U.S.

Federal regulators must evaluate three primary factors when assigning a drug’s schedule. Along with medical use, officials also examine the substance’s potential for abuse and the likelihood of psychological or physical dependence. If cannabis is found to have an accepted medical use, it would no longer meet the legal standard required for placement in Schedule 1.

Among those attending the hearing was regulatory attorney Gary Kaminsky, who said the government’s repeated focus on CAMU underscored the importance of the proceedings. He noted that proving accepted medical use would have major implications for cannabis’ current federal status.

The proposed rule relies heavily on a 2023 review by the Department of Health and Human Services, which concluded that cannabis has an accepted medical use for treating pain, chemotherapy-related nausea, and anorexia linked to certain medical conditions.

Schwartz also stated that the administrative law judge cannot reconsider the legal validity of HHS’s two-part framework for determining accepted medical use. He explained that a 2024 opinion from the DOJ’s Office of Legal Counsel found the approach legally sufficient, making it binding on the DEA and the tribunal.

Opponents of rescheduling have challenged that position, arguing the newer framework omits an earlier requirement asking whether a drug’s chemical composition is known and consistently reproducible. During cross-examination, National Drug and Alcohol Screening Association (NDASA) attorney David Evans attempted to question why federal agencies abandoned the previous five-part standard but withdrew the inquiry after objections from the DEA’s legal team.

The hearing is expected to continue through July 15, and marijuana companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) and their affiliates will be monitoring the proceedings keenly.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Archives

Select A Month
  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • September 2016
  • August 2016
  • July 2016
  • Official NewsWire Relationships

    Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

    CannabisNewsWire Currently Accepts

    Bitcoin

    Bitcoin

    Bitcoin Cash

    Bitcoin Cash

    Doge Coin

    Dogecoin

    Ethereum

    Ethereum

    Litecoin

    Litecoin

    USD Coin

    USD Coin

    Contact us: 512.354.7000